title: Acute and sub-acute effect of ferric carboxymaltose on inflammation and adhesion molecules in patients with predialysis chronic renal failure.
abstract: BACKGROUND
  Treatment with parenteral iron causes oxidative stress, inflammation and endothelial dysfunction. Ferric carboxymaltose (FCM) is a new preparation of non-dextran iron which, due to its pharmacokinetics and stability, may induce less toxicity than other iron molecules. The aim of this study was to analyse the effect of FCM on inflammation and adhesion molecules in chronic kidney disease (CKD).
  
  
  METHODS
  Forty-seven patients with predialysis CKD and iron-deficiency anaemia received a single dose of FCM (15 mg/kg, maximum dose 1 gram). At baseline and after 60 minutes (acute effect) and after 3 weeks and 3 months (sub-acute effect), we determined inflammatory markers: C-reactive protein (CRP), interleukin-6 (IL-6) and endothelial dysfunction: intercellular adhesion molecule (ICAM) and vascular adhesion molecule (VCAM).
  
  
  RESULTS
  Treatment with FCM was associated with a significant increase in haemoglobin levels: 10 (0.7) vs. 11.4 (1.3)g/dl, p<.0001. CRP, IL-6, ICAM and VCAM levels did not correlate with baseline haemoglobin or ferritin levels and there was no relationship between changes in these markers and those of haemoglobin after administration of FCM. No significant, acute or sub-acute changes occurred in any of the inflammatory or endothelial markers studied. Statin therapy was associated with lower VCAM concentrations.
  
  
  CONCLUSIONS
  Treatment with high doses of FCM in patients with predialysis CKD has no proinflammatory effect and does not alter levels of adhesion molecules ICAM and VCAM in this population.
authors: Servicio de Nefrología, Hospital Universitari Joan XXIII, Tarragona, Spain. pfk21@hotmail.com
authors: Merche
authors: M
authors: Prats
authors: Ramon
authors: R
authors: Font
authors: Carmen
authors: C
authors: García-Ruiz
authors: Carmen
authors: C
authors: Cabré
authors: Mónica
authors: M
authors: Muñoz-Cortés
authors: M Rosa
authors: MR
authors: Nogués
authors: Manel
authors: M
authors: Jariod
authors: Marta
authors: M
authors: Romeu
authors: Alberto
authors: A
authors: Martínez-Vea
mesh_terms: D000368:Aged; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000209:etiology*; D015815:Cell Adhesion Molecules / Q000187:drug effects*; D005260:Female; D005290:Ferric Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000139:chemically induced* / Q000453:epidemiology*; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008320:Maltose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies
chemical_list: D015815:Cell Adhesion Molecules; D005290:Ferric Compounds; C522335:ferric carboxymaltose; D008320:Maltose